Obesity Clinical Trials in Kansas City, Kansas

8 studies are recruiting for obesity in Kansas City, Kansas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

   This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection frac…

   Stage

   Phase 3

   Ages

   18 to 99

   Site

   University of Kansas Medical Center, Kansas City, Kansas

   Locations

   657 in total

   Run by

   Amgen

   See if you can join NCT07037459 on ClinicalTrials.gov

2. A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

   Study ASC30-302 (AURORA-2) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral ASC30 compared with placebo in participants with obesity or overweight and…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   AURORA-2 Clinical Site, Kansas City, Kansas

   Locations

   135 in total

   Run by

   Ascletis Pharma (China) Co., Limited

   See if you can join NCT07743450 on ClinicalTrials.gov

3. A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

   Study ASC30-301 (AURORA-1) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral ASC30 compared with placebo in participants with obesity or overweight wit…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   AURORA-1 Clinical Site, Kansas City, Kansas

   Locations

   122 in total

   Run by

   Ascletis Pharma (China) Co., Limited

   See if you can join NCT07743463 on ClinicalTrials.gov

4. Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

   This study is for older children, adolescents, and young adults with B-cell Acute Lymphoblastic Leukemia (B-ALL). Higher amounts of body fat is associated with resistance to chemotherapy in patients with B-ALL. Chemotherapy during the first month causes large gains in body fat in most people, even …

   Stage

   Phase 2

   Ages

   7 to 25

   Site

   Children's Mercy Hospital, Kansas City, Kansas

   Locations

   16 in total

   Run by

   Etan Orgel

   See if you can join NCT05082519 on ClinicalTrials.gov

5. Brain Outcomes With Lifestyle Change in Down Syndrome

   The goal of this study is to determine if weight loss or changes in dietary intake can help prevent of delay adults with Down syndrome from developing Alzheimer's Disease Adults with Down syndrome without dementia will be randomized to either a weight loss group or a general health education contro…

   Stage

   Not phased

   Ages

   18 to 64

   Site

   University of Kansas Medical Center, Kansas City, Kansas

   Run by

   University of Kansas Medical Center

   See if you can join NCT05985486 on ClinicalTrials.gov

6. Mitigating the Pro-inflammatory Phenotype of Obesity

   The purpose of this study is to examine the hypothesize that 4 weeks of sympathetic nerve activity (SNA) inhibition (oral clonidine) will cause a significant reduction in circulating blood concentrations and endothelial cell expression of inflammatory markers (e.g., TNF-α, IL-6). Our study is a pro…

   Stage

   Phase 1

   Ages

   18 to 79

   Site

   University of Kansas Medical Center, Kansas City, Kansas

   Run by

   University of Kansas Medical Center

   See if you can join NCT04934228 on ClinicalTrials.gov

7. Transduction of Sympathetic Neural Activity in Human Obesity Without Hypertension

   In addition to chronically elevated MSNA, there is a growing recognition that hypertension in states of insulin resistance and obesity may also be attributed to an increased vascular sensitivity to MSNA (1, 2, 13, 36-38). To study this phenomenon, we quantify vascular sensitivity to MSNA using an i…

   Stage

   Not phased

   Ages

   18 to 79

   Site

   University of Kansas Medical Center, Kansas City, Kansas

   Run by

   University of Kansas Medical Center

   See if you can join NCT06626113 on ClinicalTrials.gov

8. International Weight Control Registry

   The IWCR is a global scientific study aimed at better understanding the opportunities and barriers for reducing the prevalence of obesity by collecting information from people who have experience with weight management in their everyday lives. The investigators seek to gather information on a wide …

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Kansas Medical Center, Kansas City, Kansas

   Locations

   7 in total

   Run by

   Tufts University

   See if you can join NCT04907396 on ClinicalTrials.gov